Abstract
Neuropeptide FMRFamide (Phe-Met-Arg-Phe-NH 2) was evaluated in animal models of psychosis. FMRFamide (0.5–100 μg, i.c.v.) produced blockade of conditioned avoidance response in rats and antagonized apomorphine-induced climbing behaviour in mice. Similarly, FMRFamide at lower doses (0.1–10 μg, i.c.v.) inhibited 5-hydroxy-L-tryptophan (5-HTP)-induced head twitches in rats. These effects of the peptide were similar to haloperidol (1 mg/kg, i.p.). However, unlike haloperidol, FMRFamide per se did not induce any catalepsy in rats at the doses employed in the above paradigms. These results indicate antipsychotic-like activity for the neuropeptide FMRFamide with possible involvement of the dopaminergic/5-HT 2 systems.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
